Next Article in Journal
Antitumor, Antioxidant, and Hepatoprotective Effects of Grape Seed Oil Nanoemulsion as a Dietary Phytochemical Intervention in Ehrlich Solid Tumors
Previous Article in Journal
Lactiplantibacillus plantarum WLPL04 from Human Breast Milk Attenuates Hyperuricemia via Coordinated Purine Salvage Pathway, Renal Transporter Regulation, and Gut Microbiota Remodeling
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 17
Issue 21
10.3390/nu17213449
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

In Vivo and In Vitro Mechanisms of Equol Synthesis and Key Influencing Factors: A Critical Review

by
Tianmeng Zhang
1,2,3,
Botao Wang
3,
Chen Wang
4,
Junying Bai
4,*,
Jingwen Zhou
1,2,5,6 and
Jian Chen
1,2,5,6,*
1
Key Laboratory of Industrial Biotechnology, Ministry of Education and School of Biotechnology, Jiangnan University, 1800 Lihu Road, Wuxi 214122, China
2
Science Center for Future Foods, School of Biotechnology, Jiangnan University, Wuxi 214122, China
3
Bloomage Biotechnology Co., Ltd., Jinan 250101, China
4
Citrus Research Institute, College of Food Science, Southwest University, Chongqing 400700, China
5
Key Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education and School of Biotechnology, Jiangnan University, 1800 Lihu Road, Wuxi 214122, China
6
Jiangsu Provisional Research Center for Bioactive Product Processing Technology, Jiangnan University, 1800 Lihu Road, Wuxi 214122, China
*
Authors to whom correspondence should be addressed.
Nutrients 2025, 17(21), 3449; https://doi.org/10.3390/nu17213449 (registering DOI)
Submission received: 3 September 2025 / Revised: 15 October 2025 / Accepted: 28 October 2025 / Published: 31 October 2025
(This article belongs to the Section Nutrition and Metabolism)
Browse Figures
Versions Notes

Abstract

Background: Equol exists in two enantiomers of S-equol and R-equol. The results of cell and animal experiments, as well as clinical trials, have supported its protective effects on menopausal symptoms, aging, and cardiovascular diseases, especially S-equol, which is a naturally occurring, non-racemic isomer produced by intestinal bacteria. However, the selective response of host microorganisms to soy isoflavones limits the exploitation of equol-producing bacterial resources. Additionally, factors such as low efficiency, byproduct generation, and environmental pollution hinder the further development and the application of traditional equol synthesis techniques. Methods: Therefore, in this review, we aimed to describe the forms and scope of equol, key influencing factors (e.g., hydrogen and dietary factors) of in vivo and in vitro equol synthesis, and potential molecular mechanisms of equol produced by microorganisms. Notably, the traditional synthesis technology has effectively improved the synthesis efficiency of equol (85–96%), but the substrates and microbial species (such as Escherichia coli) remain the key influencing factors. Results: This review suggests that breakthroughs based on synthetic biology and gene editing technology will support the efficient in vitro synthesis of equol. Conclusions: This review serves as a valuable reference for future research.

1. Introduction

Numerous studies have demonstrated that the intestinal microbiota mediates the effects of dietary factors on host health and disease [1,2,3], and its core metabolites play a crucial role in its function. Bacteria in the gastrointestinal tract of humans and animals metabolize the soy isoflavone daidzein into S-equol and O-desmethylangolensin (O-DMA) [4,5]. Notably, a variable proportion of human consumers, i.e., from 10 to 60%, were found to have detectable equolplasma levels; the best 50% were designated as equol producers [6,7,8,9]. This difference may be attributed to host dietary habits and the selective results of different microorganisms.
Equol ([7-hydroxy-3-(4′-hydroxyphenyl)-chroman], C15H14O3, molecular weight 242.27) was initially isolated from the urine of a pregnant horse [10], which includes two corresponding isomers: S-equol and R-equol. Notably, epidemiological research has shown that the regular intake of soy isoflavones can reduce the occurrence of estrogen-dependent and aging-related diseases [11,12,13]. The contents of equol and equol-predicting microbial species in urine are closely related to the physiological health of the host, which can be used as a disease marker [14,15]. In particular, S-equol has pharmacokinetic parameters suitable for drug development [16,17] (Supplementary Table S1), endowing it with strong health-supporting functions [18,19,20,21,22] (Figure 1). On this basis, for example, many clinical experimental studies have demonstrated its advantageous roles in preventing age-related bone loss [23], improving skin autofluorescence and visceral fat [24], and these findings suggest its significant potential for application in clinical settings. Presently, relevant data are mainly based on the direct intake of equol or targeted enrichment of equol in the diet. However, synthesis of equol has bacterial and dietary selectivity, which poses challenges for its in vitro synthesis and in vivo regulation. In addition, traditional in vitro synthesis technology is limited by low efficiency, byproduct generation, and environmental pollution, factors that hinder the further development and application of equol.
Over the past decade, although some reviews have summarized the physiological functions, transformation, and metabolism of equol, more research has focused on its physiological effects [25,26]. Unlike these reviews, we have focused on the influence of host physiology (such as microbiome), diet, environment, and other factors on the synthesis of equol, and feasible directions for its biosynthesis. Additionally, we examined the technical and conditional limitations of equol’s applications. We determined that technological breakthroughs based on genomics, synthetic biology, and gene editing may improve the synthesis and application of equol, thereby contributing to the improvement of host genotypes and long-term human microbiota health.

2. Search Strategy and Inclusion Criteria

In this review, the PubMed (up to June 2025), Web of Science (1950 to June 2025), and Google Scholar (up to June 2025) databases were utilized to search for the relevant literature. In detail, the following terminology was used for identifying valuable studies: “equol,” “microbes,” “soybean isoflavones,” “synthesis,” “equol-producing bacteria,” “randomized,” “controlled trial,” “mice,” “review,” and “clinical trial”, “in vivo”, and “in vitro”. The included articles mainly focus on the latest literature related to equol synthesis to obtain a more comprehensive set of relevant information. Among them, some articles will be excluded if they are not related to the main theme of this review.

3. In Vitro Production of Equol

Numerous studies have demonstrated that humans have been exposed to equol-rich foods for a considerable period of time in history (Figure 2). Equol exists in fermented soy products, egg yolks [27], cabbage, and lettuce [28,29]; however, the low content in these foods limits equol’s impact on host physiological functions. People who are unable to produce endogenous equol require exogenous equol supplementation to meet their needs. Therefore, the rapid and efficient preparation of equol has become an important research topic.
Intestinal bacteria in humans and mice play a key role in producing equol. The majority of reported soy isoflavone-transforming strains are strictly anaerobic bacteria, including genera such as Asaccharobacter [30], Adlercreutzia [31], and Eggerthella [32], indicating that strains with the same transforming function have a similar taxonomic status. There are two main ways for microorganisms to produce equol (Figure 3): single-strain and co-culturing microorganisms. Minamida et al. (2006) first isolated a Gram-positive bacillus do03 strain capable of converting daidzein to equol from the cecal contents of rats [33]. They found that the rates of conversion of daidzein to equol increased by 4.7 and 4.5 times, respectively, when butyric acid and arginine were added. Compared with murine equol-producing bacteria, equol-producing bacteria isolated from human feces exhibit a higher quantity and diversity [34,35], which may be attributed to the selection of complex dietary factors within the human body. Notably, the metabolic level of equol depends on various factors, including nutritional habits, which influence the composition of the gut microbiota. This indicates that the synergistic effect of multiple equol-producing bacteria can enhance their metabolic efficiency; that is, the ability of an individual to produce equol may also be affected by co-culture with equol-producing bacteria, which provides a basis for further analysis of the differences in equol production among different individuals.
Notably, some microorganisms can only synthesize equol under mixed-culture conditions, but cannot achieve this process under single-culture conditions [34]. Similarly, when different species of microorganisms are compounded in specific proportions, the yield of equol is significantly higher than that of an isolated culture [39]. Although the interactions among these microorganisms and the key factors influencing the generation of equol remain unclear, these findings suggest the possibility of microbial compounding systems promoting the expansion of equol production, as well as the importance of nutrient elements in equol production.

3.1. Key Factors Affecting Equol Synthesis

External factors, such as dietary formulas and anaerobic conditions [34], are important factors driving the bioavailability of equol. Daidzein is a crucial nutritional component for the formation of equol [26]. The intestinal flora converts daidzein into equol. After entering the liver, equol can be further metabolized into sulfates or glucuronide conjugates [40,41]. Its metabolites can be excreted into the intestine via bile, and some of them are discharged through urine. However, isoflavones are not the only nutritional elements that are precursors to equol, and some dietary components have demonstrated similar capabilities. For example, indole-3-acetic acid plays a role in alleviating intestinal inflammation by promoting the production of equol by Bifidobacterium pseudolongum [19], suggesting that both the equol-generating phenotype and equol generation itself are influenced by dietary habits.
Furthermore, in vitro fermentation experiments demonstrated that the colonic fermentation products of indigestible carbohydrates (Figure 4), such as hydrogen, butyric acid, and propionic acid, stimulated equol production in a mixed culture [34]. The existing equol-producing bacteria are mainly anaerobic microorganisms, and most related studies have been conducted under anaerobic conditions. Fecal inoculates of equol producers metabolize daidzein into equol, whereas fecal inoculates of non-equol producers do not produce equol. However, some strains produced O-DMA and dihydrodaidzein, and there were significant differences in the responses of soy isoflavone metabolism in different individuals to the effects of antibiotics [42]. To address this issue, researchers have improved the transformation efficiency and content of equol by optimizing the microbial metabolic environment. Some researchers have established an optimized cascade system by regulating the intensity of gene expression. After optimizing the fermentation conditions, a high S-equol production titer of 3418.5 mg/L was generated [43]. Notably, during the conversion of daidzein into equol, hydrogen gas is consumed by equol-producing bacteria. Under in vitro simulated gastrointestinal conditions, microbial equol production activity weakens the methanogenic and sulfur-producing activities of active hydrogen-consuming bacteria [44], suggesting that hydrogen gas content is one of the main influencing factors affecting equol production. These studies provide a basis for the in vitro synthesis of equol and optimization of related processes.

3.2. Biosynthesis of Equol

Chemical synthesis is an important in vitro source of equol. It is mainly based on using isoflavones and chemical reagents to synthesize equol through multi-level chemical reactions. Pelissero et al. (1991) have obtained equol via catalytic hydrogenation of daidzein on palladium/charcoal-EtOH under a hydrogen atmosphere [47]. Although this method showed a highly efficient synthesis efficiency, it has low purity (35%). Based on this, a new chiral stationary phase, Chiralpak® IA, was used for the separation of R- and S-equol. It has good potential in the resolution of the enantiomeric selectivity of equol and can retain the chiral isomers, which is helpful for further evaluation of its metabolites and their enantiomers’ biological effects [48]. Subsequently, many studies have been conducted with the aim of continuously improving chemical synthesis to effectively increase the equol yield [49]. However, the extensive use of chemical reagents inevitably leads to problems such as low purity, the generation of byproducts, and organic reagent residues. The development of efficient, environmentally friendly, and low-cost strategies for the synthesis of equol is currently a research hotspot.
In recent years, technologies such as synthetic biology, genomics, and gene editing have shown promise for the rapid and efficient production of equol. Synthetic biology mainly uses biotechnology and intelligent means as the core and organisms as the chassis to process functional substances. By introducing exogenous enzymes or modifying endogenous enzymes, new biosynthetic pathways can be constructed to accumulate target products (Figure 5). Some studies have further emphasized the potential correlation between the dznr gene and S-equol content [50,51,52], providing prospects for enhancing in vitro S-equol production. At least four key metabolic enzymes are required to convert daidzein into equol in vitro: DZNR (Daidzein Reductase); DHDR (Dihydrodaidzein Reductase); THDR (Tetrahydrodaidzein Reductase); DDRC (Dihydrodaidzein Racemase). Introducing DZNR, DHDR, DDRC, and THDR enzymes into E. coli BL21 (DE3) cells were shown to be an efficient multi-enzyme cascade technique, with a conversion rate of approximately 85.9% [43]. Vazquez et al. (2021) synthesized four genes encoding key enzymes involved in equol production in Adlercreutzia equolifaciens DSM19450T, cloned them into a vector derived from pUC, and introduced this vector into E. coli. Daidzein and dihydrodaidzein were added to the culture medium, and the recombinant E. coli produced equol [31]. Notably, in vitro S-equol synthesis efficiency is affected by the external environment (e.g., hydrogen and oxygen). Further application of engineered strains has played a role in the continuous improvement and increased efficiency of equol production (Supplementary Table S2). Wang et al. (2023) constructed recombinant E. coli for the biosynthesis of S-equol from soy whey, co-expressing sucrase and α-galactosidase, endowing E. coli with the ability to utilize sucrose, raffinose, and trehalose [53]. The optimal strain produced 91.5 mg/L of S-equol in concentrated soybean milk, with a yield of 0.96 mol/mol substrate [53]. The metabolic process of converting soy isoflavones into equol requires strict anaerobic conditions. H2 is a metabolic by-product produced by intestinal microorganisms during anaerobic fermentation. Its presence indicates the formation of an anaerobic environment, rather than directly participating in the synthesis of equol. Notably, in some studies, the physiological characteristics and environmental adaptability of equol-producing bacteria have been further modified. Li et al. (2018) constructed and screened transposon mutagenesis libraries to isolate mutant E. coli BL21 that is resistant to S-equol, thereby overcoming its inhibitory effect on bacterial growth [54]. The conversion of daidzein into S-equol for efficient production under aerobic conditions provides a convenient method for the in vitro production of equol.
As a new interdisciplinary field, synthetic biology research provides technical support and improvement directions for the in vitro synthesis of equol. However, problems such as the high requirements of synthetic biology technology, a lack of laws and regulations for safety supervision, and unclear protection of intellectual property rights restrict its large-scale promotion in actual production. Furthermore, although oxygen-tolerant bacteria have been developed, these strains grow slowly under aerobic conditions. Screening for oxygen-tolerant strains that can efficiently transform into equol remains the focus of future research.

4. Restrictive Factors in the Development of Equol Functions

Notably, there is a difference in the host’s ability to produce equol between humans and animals. Cross-species comparisons between humans and rats indicate that the catalytic efficiency of S-equol production in rats is 210 times that in humans [55], which is mainly attributed to the differences between the intrinsic physiological structures and characteristics of animals and humans. Specific bacteria in human and animal intestines mediate the conversion of isoflavones to equol, and there are significant inter-individual differences in daidzein metabolism. After consuming soybeans or soy extract, approximately 30–50% of people produce equol, and approximately 80–90% produce O-DMA [56]. Direct evidence suggests that only some humans can generate S-equol through microbial metabolism, and this effect is influenced by the sex of the host [57]. Furthermore, among randomized controlled trials involving 110 women, the generation capacity of endogenous equol may have been affected by the vascular function of the host [58]. These results reveal that intrinsic factors such as host sex, intestinal microbiota, and intestinal diseases influence equol generation and transformation efficiency. Furthermore, there are differences in the ability of human and animal models to metabolize equol. Studies have shown significant differences in S-equol metabolic capacity between the liver and intestine in humans, monkeys, dogs, rats, and mice [40]. Additionally, a substantial amount of clinical data provides evidence of a correlation between changes in equol content in plasma and urine and the host’s health status [15,59]. For example, there is a significant difference in daidzein excretion between equol producers and non-equol producers. This partly explains the difference in daidzein bioavailability after soy isoflavone ingestion [60]. In addition, exposure to equol was associated with increased breast cancer risk [61]. There is evidence that equol has a relatively long half-life [17], allowing it to exist in the host for a prolonged period, increasing its opportunities to cross the intestinal and brain barriers [62], thereby affecting the host’s health. Equol mainly exists in plasma in the form of 7-O-glucosidate derivatives [63], which makes it difficult to distinguish between the biologically active forms at the tissue and cellular levels. These factors lead to uncertainties in the functional research and development of equol and in the detection of clinical data. Another challenge is the insufficient understanding of the types and functions of microorganisms involved in equol production. Currently, the vast majority of the reported strains that transform soy isoflavones are strictly anaerobic bacteria and have mainly been studied at the genus level. Moreover, identification of related microorganisms relies mostly on traditional culture methods and microbiological techniques. These factors limit our understanding of the potential value and role of intestinal microorganisms, restricting the further development of related technologies.

5. Promotion of Emerging Technologies in Equol-Related Research

The development of models represented by germ-free animals provides the possibility of clarifying the causal relationship between core species and intestinal microbiota equol synthesis. Liang et al. (2020) constructed pseudo Germ-Free mice using broad-spectrum antibiotic interference and established a humanized fecal microbiota mouse model through human fecal microbiota transplantation to simulate the intestinal microbiota of adult human equol producers [64]. The ability to produce equol was partially transferred from human donors to humanized mice [64] and was affected by antibiotics [42]. On this basis, when soybeans were fed to sterile animals and newborn infants lacking a well-developed microbiota, equol could not be detected in the urine [65], whereas when soybeans cultured with fecal microbiota from equol-producing adults were fed to the subjects, they produced S-equol. These results suggest that the yield of equol generated may not depend on the number of equol-producing bacteria but on the physiological characteristics (e.g., antibiotic tolerance) of specific equol-producing bacteria, and that high microbial diversity may increase the yield of equol [66]. Although it has been theorized that the effects of antibiotics on microbial diversity and abundance might be the main reason for the lack of equol production in some organisms, this phenomenon occurred in only 20% of the participants [67]. This result not only provides direct evidence that the gut microbiota drives the synthesis of equol.
Computer models can intuitively predict and track the modification, degradation, and metabolic processes of equol in the human intestinal tract, thereby providing an accurate reference for potential equol function prediction and development. Some studies have employed in vitro computer simulation methods, including physiologically based pharmacokinetic (PBPK) modeling, to investigate the effects of gut microbiota metabolism on the conversion of daidzein to S-equol and the resulting estrogen activity. This in vitro computer simulation method includes kinetic quantitative analysis of daidzein conversion to microbial metabolites and the establishment of a rat PBPK model that includes intestinal microbiota metabolism [55]. These techniques can be used to explore the role of the gut microbiota in the in vivo effects of equol, predict conditions in the human body, and clarify potential species differences. Goris et al. (2021) [68] analyzed the unified human gastrointestinal protein catalog using known flavonoid modification enzyme sequences as queries and quantified the genes encoding the supposed flavonoid modification enzymes [55]. The enzyme responsible for the conversion of daidzein to equol was more abundant in A. equolifaciens and an uncharacterized Eggerthellaceae species, indicating the hitherto uncharacterized potential of these bacteria to convert daidzein to equol. This finding has substantial implications for further biochemical and microbiological studies on equol transformation. In addition, culturomics combines multiple culture conditions with rapid identification techniques to identify new bacteria, greatly enhancing our understanding of bacteria. On this basis, the application of multi-omics technology, with the continuous advancement of artificial intelligence technologies such as deep learning, will play a more important role in the mining of intestinal microorganisms by improving the efficiency and accuracy of mining. The integration of multi-omics technologies, such as metagenomics, transcriptomics, proteomics, and metabolomics, will provide a more comprehensive understanding of the functions and metabolic pathways of gut microbiota.

6. Future Research

The in vitro synthesis of equol remains the main choice for non-equol producers. However, some issues need to be addressed in future research: (1) The synthesis of equol is affected by various factors, such as nutrient sources and oxygen. In the future, by integrating transcriptomics, metabolomics, and molecular biology techniques, the gene regulatory networks and metabolic pathways of aerobic bacteria can be systematically analyzed, laying the foundation for improving their synthetic efficiency. (2) Equol synthesis and metabolic efficiency vary among different bacteria; there may be a synergistic effect between multiple bacteria. The production of equol is not accomplished independently by a single strain, but rather requires the cooperation of multiple microorganisms through metabolic synergy or enzymatic succession. Therefore, it is necessary to conduct a detailed analysis of the signal transduction mechanisms among different strains and reveal the molecular regulatory network for metabolic synergy. (3) Due to the limitations of targeted isolation technology for intestinal microbiota, a large proportion of microorganisms have not been obtained in solid strains. It is necessary to clarify the complex interaction mechanisms among diet, equol, and intestinal microbiota. (4) Considering that there are significant differences in the ability of individuals to metabolize soy isoflavones into equol, it is necessary to identify whether individuals are equol metabolizers, so as to develop more effective nutritional intervention strategies for specific individuals.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/nu17213449/s1, Table S1: The species/sex differences & pharmacokinetics of equol [16,17,69]; Table S2: The quantitative synthesis for in vitro production [46,53,54,70].

Author Contributions

T.Z. and B.W.: Investigation, Writing—Original draft preparation. C.W.: Visualization, Investigation, Funding acquisition. J.B.: Visualization, Investigation, Writing-Reviewing and Editing, Funding acquisition. J.Z.: Visualization, Investigation. J.C.: Writing—Reviewing and Editing, Supervision, Funding acquisition. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Foundation for Innovative Research Groups of the National Natural Science Foundation of China (32021005), Technology Innovation and Application Development Program of Chongqing (CSTB2024TIAD-LUX0002, CSTB2023TIAD-KPX0043), and Fundamental Research Funds for the Central Universities (SWU-KQ22076).

Data Availability Statement

Not applicable. Figures were created with biorender.com.

Conflicts of Interest

Tianmeng Zhang and Botao Wang were employed by Bloomage Biotechnology Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Cao, L.; Wu, Y.; Liu, K.-Y.; Qi, N.-X.; Zhang, J.; Tie, S.-S.; Li, X.; Tian, P.-P.; Gu, S.-B. Cornus officinalis vinegar alters the gut microbiota, regulating lipid droplet changes in nonalcoholic fatty liver disease model mice. Food Med. Homol. 2024, 1, 9420002. [Google Scholar] [CrossRef]
  2. Liu, Y.-F.; Ling, N.; Zhang, B.; Chen, C.; Mo, X.-N.; Cai, J.-Y.; Tan, X.-D.; Yu, Q.-M. Flavonoid-rich mulberry leaf extract modulate lipid metabolism, antioxidant capacity, and gut microbiota in high-fat diet-induced obesity: Potential roles of FGF21 and SOCS2. Food Med. Homol. 2024, 1, 9420016. [Google Scholar] [CrossRef]
  3. Wang, C.; Bai, J.; Wang, B.; Yu, L.; Tian, F.; Zhao, J.; Zhang, H.; Suo, H.; Chen, W.; Zhai, Q. Stachyose modulates gut microbiota and alleviates DSS-induced ulcerative colitis in mice. Food Sci. Hum. Wellness 2023, 12, 2211–2220. [Google Scholar] [CrossRef]
  4. Fujitani, M.; Mizushige, T.; Bhattarai, K.; Adhikari, S.; Ishikawa, J.; Kishida, T. Dietary daidzein induces accumulation of S-equol in enterohepatic circulation to far higher levels than that of daidzein in female rats with and without ovariectomy. Biomed. Res. 2019, 40, 97–105. [Google Scholar] [CrossRef] [PubMed]
  5. Ohtomo, T.; Uehara, M.; Peñalvo, J.L.; Adlercreutz, H.; Katsumata, S.; Suzuki, K.; Takeda, K.; Masuyama, R.; Ishimi, Y. Comparative activities of daidzein metabolites, equol and O-desmethylangolensin, on bone mineral density and lipid metabolism in ovariectomized mice and in osteoclast cell cultures. Eur. J. Nutr. 2008, 47, 273–279. [Google Scholar] [CrossRef]
  6. Bolca, S.; Possemiers, S.; Herregat, A.; Huybrechts, I.; Heyerick, A.; De Vriese, S.; Verbruggen, M.; Depypere, H.; De Keukeleire, D.; Bracke, M.; et al. Microbial and dietary factors are associated with the equol producer phenotype in healthy postmenopausal women. J. Nutr. 2007, 137, 2242–2246. [Google Scholar] [CrossRef] [PubMed]
  7. Hall, M.C.; O’Brien, B.; McCormack, T. Equol producer status, salivary estradiol profile and urinary excretion of isoflavones in Irish Caucasian women, following ingestion of soymilk. Steroids 2007, 72, 64–70. [Google Scholar] [CrossRef]
  8. Peeters, P.H.; Slimani, N.; van der Schouw, Y.T.; Grace, P.B.; Navarro, C.; Tjonneland, A.; Olsen, A.; Clavel-Chapelon, F.; Touillaud, M.; Boutron-Ruault, M.C.; et al. Variations in plasma phytoestrogen concentrations in European adults. J. Nutr. 2007, 137, 1294–1300. [Google Scholar] [CrossRef]
  9. Setchell, K.D.; Cole, S.J. Method of defining equol-producer status and its frequency among vegetarians. J. Nutr. 2006, 136, 2188–2193. [Google Scholar] [CrossRef]
  10. Marrian, G.F.; Haslewood, G.A. Equol, a new inactive phenol isolated from the ketohydroxyoestrin fraction of mares’ urine. Biochem. J. 1932, 26, 1227–1232. [Google Scholar] [CrossRef]
  11. Pokushalov, E.; Ponomarenko, A.; Garcia, C.; Kasimova, L.; Pak, I.; Shrainer, E.; Romanova, A.; Kudlay, D.; Johnson, M.; Miller, R. Assessing the combined effects of Black Cohosh, Soy Isoflavones, and SDG Lignans on menopausal symptoms: A randomized, double-blind, placebo-controlled clinical trial. Eur. J. Nutr. 2025, 64, 138. [Google Scholar] [CrossRef]
  12. Lu, L.W.; Chen, N.W.; Brunder, D.G.; Nayeem, F.; Nagamani, M.; Nishino, T.K.; Anderson, K.E.; Khamapirad, T. Soy isoflavones decrease fibroglandular breast tissue measured by magnetic resonance imaging in premenopausal women: A 2-year randomized double-blind placebo controlled clinical trial. Clin. Nutr. ESPEN 2022, 52, 158–168. [Google Scholar] [CrossRef] [PubMed]
  13. Luan, H.; Liu, Q.; Guo, Y.; Fan, H.; A, S.; Lin, J. Effects of soy isoflavones on menopausal symptoms in perimenopausal women: A systematic review and meta-analysis. PeerJ 2025, 13, e19715. [Google Scholar] [CrossRef]
  14. Hamaura, K.; Murakami, H.; Tamura, A.; Matsuki, K.; Sato, E.; Tanabe, J.; Yanagimachi, M.; Oishi, M.; Iino, K.; Okuyama, S.; et al. Association between equol producers and type 2 diabetes mellitus among Japanese older adults. J. Diabetes Investig. 2023, 14, 707–715. [Google Scholar] [CrossRef]
  15. Liang, S.; Zhang, H.; Mo, Y.; Li, Y.; Zhang, X.; Cao, H.; Xie, S.; Wang, D.; Lv, Y.; Wu, Y.; et al. Urinary equol and equol-predicting microbial species are favorably associated with cardiometabolic risk markers in Chinese adults. J. Am. Heart Assoc. 2024, 13, e034126. [Google Scholar] [CrossRef]
  16. AnandaKumar, S.R.; Handral, M.; Seekallu, S. Bioavailability study of enantiopure (S)-Equol in CD(SD)IGS rats. Sci. Rep. 2025, 15, 3141. [Google Scholar] [CrossRef] [PubMed]
  17. Legette, L.L.; Prasain, J.; King, J.; Arabshahi, A.; Barnes, S.; Weaver, C.M. Pharmacokinetics of equol, a soy isoflavone metabolite, changes with the form of equol (dietary versus intestinal production) in ovariectomized rats. J. Agric. Food Chem. 2014, 62, 1294–1300. [Google Scholar] [CrossRef] [PubMed]
  18. Cheong, S.H.; Furuhashi, K.; Ito, K.; Nagaoka, M.; Yonezawa, T.; Miura, Y.; Yagasaki, K. Antihyperglycemic effect of equol, a daidzein derivative, in cultured L6 myocytes and ob/ob mice. Mol. Nutr. Food Res. 2014, 58, 267–277. [Google Scholar] [CrossRef] [PubMed]
  19. Li, M.; Han, X.; Sun, L.; Liu, X.; Zhang, W.; Hao, J. Indole-3-acetic acid alleviates DSS-induced colitis by promoting the production of R-equol from Bifidobacterium pseudolongum. Gut Microbes 2024, 16, 2329147. [Google Scholar] [CrossRef]
  20. Lu, C.; Gao, R.; Zhang, Y.; Jiang, N.; Chen, Y.; Sun, J.; Wang, Q.; Fan, B.; Liu, X.; Wang, F. S-equol, a metabolite of dietary soy isoflavones, alleviates lipopolysaccharide-induced depressive-like behavior in mice by inhibiting neuroinflammation and enhancing synaptic plasticity. Food Funct. 2021, 12, 5770–5778. [Google Scholar] [CrossRef]
  21. Tanaka, M.; Fujii, S.; Inoue, H.; Takahashi, N.; Ishimi, Y.; Uehara, M. (S)-equol is more effective than (R)-equol in inhibiting osteoclast formation and enhancing osteoclast apoptosis, and reduces estrogen deficiency-induced bone loss in mice. J. Nutr. 2022, 152, 1831–1842. [Google Scholar] [CrossRef]
  22. Zhang, J.; Ren, L.; Yu, M.; Liu, X.; Ma, W.; Huang, L.; Li, X.; Ye, X. S-equol inhibits proliferation and promotes apoptosis of human breast cancer MCF-7 cells via regulating miR-10a-5p and PI3K/AKT pathway. Arch. Biochem. Biophys. 2019, 672, 108064. [Google Scholar] [CrossRef]
  23. Corbi, G.; Nobile, V.; Conti, V.; Cannavo, A.; Sorrenti, V.; Medoro, A.; Scapagnini, G.; Davinelli, S. Equol and Resveratrol Improve Bone Turnover Biomarkers in Postmenopausal Women: A Clinical Trial. Int. J. Mol. Sci. 2023, 24, 12063. [Google Scholar] [CrossRef]
  24. Yoshikata, R.; Myint, K.Z.Y.; Ohta, H.; Ishigaki, Y. Effects of an equol-containing supplement on advanced glycation end products, visceral fat and climacteric symptoms in postmenopausal women: A randomized controlled trial. PLoS ONE 2021, 16, e0257332. [Google Scholar] [CrossRef] [PubMed]
  25. Hod, R.; Maniam, S.; Mohd Nor, N.H. A systematic review of the effects of equol (soy metabolite) on breast cancer. Molecules 2021, 26, 1105. [Google Scholar] [CrossRef]
  26. Mayo, B.; Vázquez, L.; Flórez, A.B. Equol: A bacterial metabolite from the daidzein isoflavone and its presumed beneficial health effects. Nutrients 2019, 11, 2231. [Google Scholar] [CrossRef]
  27. Saitoh, S.; Sato, T.; Harada, H.; Matsuda, T. Biotransformation of soy isoflavone-glycosides in laying hens: Intestinal absorption and preferential accumulation into egg yolk of equol, a more estrogenic metabolite of daidzein. Biochim. Et Biophys. Acta 2004, 1674, 122–130. [Google Scholar] [CrossRef]
  28. Androgens, M.H. Anti-oxidant and anti-aging properties of equol in prostate health (BPH). Open J. Endocr. Metab. Dis. 2014, 4, 1–12. [Google Scholar]
  29. Gong, Y.; Lv, J.; Pang, X.; Zhang, S.; Zhang, G.; Liu, L.; Wang, Y.; Li, C. Advances in the metabolic mechanism and functional characteristics of equol. Foods 2023, 12, 2334. [Google Scholar] [CrossRef] [PubMed]
  30. Thawornkuno, C.; Tanaka, M.; Sone, T.; Asano, K. Biotransformation of daidzein to equol by crude enzyme from Asaccharobacter celatus AHU1763 required an anaerobic environment. Biosci. Biotechnol. Biochem. 2009, 73, 1435–1438. [Google Scholar] [CrossRef]
  31. Vázquez, L.; Flórez, A.B.; Rodríguez, J.; Mayo, B. Heterologous expression of equol biosynthesis genes from Adlercreutzia equolifaciens. FEMS Microbiol. Lett. 2021, 368, fnab082. [Google Scholar] [CrossRef]
  32. Kawada, Y.; Yokoyama, S.; Yanase, E.; Niwa, T.; Suzuki, T. The production of S-equol from daidzein is associated with a cluster of three genes in Eggerthella sp. YY7918. Biosci. Microbiota Food Health 2016, 35, 113–121. [Google Scholar] [CrossRef]
  33. Minamida, K.; Tanaka, M.; Abe, A.; Sone, T.; Tomita, F.; Hara, H.; Asano, K. Production of equol from daidzein by gram-positive rod-shaped bacterium isolated from rat intestine. J. Biosci. Bioeng. 2006, 102, 247–250. [Google Scholar] [CrossRef]
  34. Decroos, K.; Vanhemmens, S.; Cattoir, S.; Boon, N.; Verstraete, W. Isolation and characterisation of an equol-producing mixed microbial culture from a human faecal sample and its activity under gastrointestinal conditions. Arch. Microbiol. 2005, 183, 45–55. [Google Scholar] [CrossRef]
  35. Yokoyama, S.; Suzuki, T. Isolation and characterization of a novel equol-producing bacterium from human feces. Biosci Biotechnol Biochem 2008, 72, 2660–2666. [Google Scholar] [CrossRef] [PubMed]
  36. Matthies, A.; Clavel, T.; Gütschow, M.; Engst, W.; Haller, D.; Blaut, M.; Braune, A. Conversion of daidzein and genistein by an anaerobic bacterium newly isolated from the mouse intestine. Appl. Environ. Microbiol. 2008, 74, 4847–4852. [Google Scholar] [CrossRef] [PubMed]
  37. Jin, J.S.; Nishihata, T.; Kakiuchi, N.; Hattori, M. Biotransformation of C-glucosylisoflavone puerarin to estrogenic (3S)-equol in co-culture of two human intestinal bacteria. Biol. Pharm. Bull. 2008, 31, 1621–1625. [Google Scholar] [CrossRef]
  38. Wang, X.L.; Hur, H.G.; Lee, J.H.; Kim, K.T.; Kim, S.I. Enantioselective synthesis of S-equol from dihydrodaidzein by a newly isolated anaerobic human intestinal bacterium. Appl. Environ. Microbiol. 2005, 71, 214–219. [Google Scholar] [CrossRef]
  39. Fan, H.; Liu, X.; Liu, D.; Zhao, C.; Chen, J.; Cheng, Y. The production of equol by mixed culture fermentation of Streptococcus faecium and Enterobacter. Food Sci. Technol. Res 2011, 36, 2–6. [Google Scholar]
  40. Isobe, T.; Ohkawara, S.; Ochi, S.; Tanaka-Kagawa, T.; Hanioka, N. S-equol glucuronidation in liver and intestinal microsomes of humans, monkeys, dogs, rats, and mice. Food Chem. Toxicol. 2019, 131, 110542. [Google Scholar] [CrossRef]
  41. Wang, Y.; Zhang, Y. Advances on the study of equol metabolism in human. Wei Sheng Yan Jiu = J. Hyg. Res. 2010, 39, 787–789. [Google Scholar]
  42. Atkinson, C.; Berman, S.; Humbert, O.; Lampe, J.W. In vitro incubation of human feces with daidzein and antibiotics suggests interindividual differences in the bacteria responsible for equol production. J. Nutr. 2004, 134, 596–599. [Google Scholar] [CrossRef] [PubMed]
  43. Deng, H.; Gao, S.; Zhang, W.; Zhang, T.; Li, N.; Zhou, J. High titer of (S)-equol synthesis from daidzein in Escherichia coli. ACS Synth. Biol. 2022, 11, 4043–4053. [Google Scholar] [CrossRef]
  44. Bolca, S.; Verstraete, W. Microbial equol production attenuates colonic methanogenesis and sulphidogenesis in vitro. Anaerobe 2010, 16, 247–252. [Google Scholar] [CrossRef]
  45. Beschkov, V.; Parvanova-Mancheva, T.; Vasileva, E. Experimental study of bio-hydrogen production by Clostridium beijerinckii from different substrates. Energies 2023, 16, 2747. [Google Scholar] [CrossRef]
  46. Hylemon, P.B.; Harris, S.C.; Ridlon, J.M. Metabolism of hydrogen gases and bile acids in the gut microbiome. FEBS Lett. 2018, 592, 2070–2082. [Google Scholar] [CrossRef]
  47. Pelissero, C.; Bennetau, B.; Babin, P.; Le Menn, F.; Dunogues, J. The estrogenic activity of certain phytoestrogens in the Siberian sturgeon Acipenser baeri. J. Steroid Biochem. Mol. Biol. 1991, 38, 293–299. [Google Scholar] [CrossRef]
  48. Shinkaruk, S.; Carreau, C.; Flouriot, G.; Bennetau-Pelissero, C.; Potier, M. Comparative effects of R- and S-equol and implication of transactivation functions (AF-1 and AF-2) in estrogen receptor-induced transcriptional activity. Nutrients 2010, 2, 340–354. [Google Scholar] [CrossRef] [PubMed]
  49. Yang, S.; Zhu, S.-F.; Zhang, C.-M.; Song, S.; Yu, Y.-B.; Li, S.; Zhou, Q.-L. Enantioselective iridium-catalyzed hydrogenation of α-arylcinnamic acids and synthesis of (S)-equol. Tetrahedron 2012, 68, 5172–5178. [Google Scholar] [CrossRef]
  50. Hu, Y.F.; Luo, S.; Wang, S.Q.; Chen, K.X.; Zhong, W.X.; Li, B.Y.; Cao, L.Y.; Chen, H.H.; Yin, Y.S. Exploring functional genes’ correlation with (S)-equol concentration and new daidzein racemase identification. Appl. Environ. Microbiol. 2024, 90, e0000724. [Google Scholar] [CrossRef]
  51. Shimada, Y.; Takahashi, M.; Miyazawa, N.; Ohtani, T.; Abiru, Y.; Uchiyama, S.; Hishigaki, H. Identification of two novel reductases involved in equol biosynthesis in Lactococcus strain 20–92. J. Mol. Microbiol. Biotechnol. 2011, 21, 160–172. [Google Scholar] [CrossRef]
  52. Shimada, Y.; Yasuda, S.; Takahashi, M.; Hayashi, T.; Miyazawa, N.; Sato, I.; Abiru, Y.; Uchiyama, S.; Hishigaki, H. Cloning and expression of a novel NADP(H)-dependent daidzein reductase, an enzyme involved in the metabolism of daidzein, from equol-producing Lactococcus strain 20-92. Appl. Environ. Microbiol. 2010, 76, 5892–5901. [Google Scholar] [CrossRef] [PubMed]
  53. Wang, Z.; Li, X.; Azi, F.; Dai, Y.; Xu, Z.; Yu, L.; Zhou, J.; Dong, M.; Xia, X. Biosynthesis of (S)-Equol from Soy Whey by Metabolically Engineered Escherichia coli. J. Agric. Food Chem. 2023, 71, 6110–6119. [Google Scholar] [CrossRef] [PubMed]
  54. Li, H.; Mao, S.; Chen, H.; Zhu, L.; Liu, W.; Wang, X.; Yin, Y. To Construct an Engineered (S)-Equol Resistant E. coli for in Vitro (S)-Equol Production. Front. Microbiol. 2018, 9, 1182. [Google Scholar] [CrossRef]
  55. Wang, Q.; Spenkelink, B.; Boonpawa, R.; Rietjens, I. Use of Physiologically Based Pharmacokinetic Modeling to Predict Human Gut Microbial Conversion of Daidzein to S-Equol. J. Agric. Food Chem. 2022, 70, 343–352. [Google Scholar] [CrossRef]
  56. Atkinson, C.; Frankenfeld, C.L.; Lampe, J.W. Gut bacterial metabolism of the soy isoflavone daidzein: Exploring the relevance to human health. Exp. Biol. Med. (Maywood) 2005, 230, 155–170. [Google Scholar] [CrossRef]
  57. Soukup, S.T.; Helppi, J.; Müller, D.R.; Zierau, O.; Watzl, B.; Vollmer, G.; Diel, P.; Bub, A.; Kulling, S.E. Phase II metabolism of the soy isoflavones genistein and daidzein in humans, rats and mice: A cross-species and sex comparison. Arch. Toxicol. 2016, 90, 1335–1347. [Google Scholar] [CrossRef]
  58. Törmälä, R.; Appt, S.; Clarkson, T.B.; Groop, P.H.; Rönnback, M.; Ylikorkala, O.; Mikkola, T.S. Equol production capability is associated with favorable vascular function in postmenopausal women using tibolone; no effect with soy supplementation. Atherosclerosis 2008, 198, 174–178. [Google Scholar] [CrossRef] [PubMed]
  59. Yoshikata, R.; Myint, K.Z.Y.; Taguchi, J. Comparison of blood and urine concentrations of equol by LC-MS/MS method and factors associated with equol production in 466 Japanese men and women. PLoS ONE 2024, 19, e0288946. [Google Scholar] [CrossRef]
  60. Vergne, S.; Titier, K.; Bernard, V.; Asselineau, J.; Durand, M.; Lamothe, V.; Potier, M.; Perez, P.; Demotes-Mainard, J.; Chantre, P.; et al. Bioavailability and urinary excretion of isoflavones in humans: Effects of soy-based supplements formulation and equol production. J. Pharm. Biomed. Anal. 2007, 43, 1488–1494. [Google Scholar] [CrossRef]
  61. Grace, P.B.; Taylor, J.I.; Low, Y.L.; Luben, R.N.; Mulligan, A.A.; Botting, N.P.; Dowsett, M.; Welch, A.A.; Khaw, K.T.; Wareham, N.J.; et al. Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European prospective investigation of cancer and nutrition-norfolk. Cancer Epidemiol. Biomark. Prev. 2004, 13, 698–708. [Google Scholar] [CrossRef]
  62. Johnson, S.L.; Park, H.Y.; Vattem, D.A.; Grammas, P.; Ma, H.; Seeram, N.P. Equol, a Blood-Brain Barrier Permeable Gut Microbial Metabolite of Dietary Isoflavone Daidzein, Exhibits Neuroprotective Effects against Neurotoxins Induced Toxicity in Human Neuroblastoma SH-SY5Y Cells and Caenorhabditis elegans. Plant Foods Hum. Nutr. 2020, 75, 512–517. [Google Scholar] [CrossRef]
  63. Gardana, C.; Simonetti, P. Long-term kinetics of daidzein and its main metabolites in human equol-producers after soymilk intake: Identification of equol-conjugates by UPLC-orbitrap-MS and influence of the number of transforming bacteria on plasma kinetics. Int. J. Food Sci. Nutr. 2017, 68, 496–506. [Google Scholar] [CrossRef] [PubMed]
  64. Liang, W.; Zhao, L.; Zhang, J.; Fang, X.; Zhong, Q.; Liao, Z.; Wang, J.; Guo, Y.; Liang, H.; Wang, L. Colonization Potential to Reconstitute a Microbe Community in Pseudo Germ-Free Mice After Fecal Microbe Transplant From Equol Producer. Front. Microbiol. 2020, 11, 1221. [Google Scholar] [CrossRef]
  65. Brown, N.M.; Galandi, S.L.; Summer, S.S.; Zhao, X.; Heubi, J.E.; King, E.C.; Setchell, K.D. S-(-)equol production is developmentally regulated and related to early diet composition. Nutr. Res. 2014, 34, 401–409. [Google Scholar] [CrossRef]
  66. Yoshikata, R.; Myint, K.Z.; Ohta, H.; Ishigaki, Y. Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: Baseline findings from a placebo-controlled intervention trial. Menopause 2019, 26, 273–285. [Google Scholar] [CrossRef] [PubMed]
  67. Setchell, K.D.; Brown, N.M.; Summer, S.; King, E.C.; Heubi, J.E.; Cole, S.; Guy, T.; Hokin, B. Dietary factors influence production of the soy isoflavone metabolite s-(-)equol in healthy adults. J. Nutr. 2013, 143, 1950–1958. [Google Scholar] [CrossRef] [PubMed]
  68. Goris, T.; Cuadrat, R.R.C.; Braune, A. Flavonoid-Modifying Capabilities of the Human Gut Microbiome-An In Silico Study. Nutrients 2021, 13, 2688. [Google Scholar] [CrossRef]
  69. Schwen, R.J.; Nguyen, L.; Plomley, J.B.; Jackson, R.L. Toxicokinetics and lack of uterotropic effect of orally administered S-equol. Food Chem. Toxicol. 2012, 50, 1741–1748. [Google Scholar] [CrossRef]
  70. Lee, P.G.; Kim, J.; Kim, E.J.; Jung, E.; Pandey, B.P.; Kim, B.G. P212A Mutant of Dihydrodaidzein Reductase Enhances (S)-Equol Production and Enantioselectivity in a Recombinant Escherichia coli Whole-Cell Reaction System. Appl. Environ. Microbiol. 2016, 82, 1992–2002. [Google Scholar] [CrossRef]
Nutrients 17 03449 g001
Figure 1. The potential physiological functions of Equol. Indole-3-acetic acid plays a role in alleviating intestinal inflammation by promoting the production of equol by Bifidobacterium pseudolongum in mice [19]; S-equol can inhibit osteoclast differentiation and stimulate apoptosis of mature osteoclasts via inducing caspase-3/7 activity in BMCs and RAW 264.7 cells [21]; S-equol can alleviate the depressive-like behavior and neuroinflammation induced by LPS via the TLR4/NF-κB signaling pathway in mice [20]; S-equol can lower the fasting blood sugar level and inhibit the gene expression of liver enzymes related to glucose metabolism in mice, showed a potential anti-diabetic roles [18]; S-equol showed an anti-breast cancer role via up-regulating miR-10a-5p and inhibiting the PI3K/AKT pathway [22]. This Figure was created in BioRender. (2025) https://BioRender.com/fgldagm (accessed on 25 August 2025).
Figure 1. The potential physiological functions of Equol. Indole-3-acetic acid plays a role in alleviating intestinal inflammation by promoting the production of equol by Bifidobacterium pseudolongum in mice [19]; S-equol can inhibit osteoclast differentiation and stimulate apoptosis of mature osteoclasts via inducing caspase-3/7 activity in BMCs and RAW 264.7 cells [21]; S-equol can alleviate the depressive-like behavior and neuroinflammation induced by LPS via the TLR4/NF-κB signaling pathway in mice [20]; S-equol can lower the fasting blood sugar level and inhibit the gene expression of liver enzymes related to glucose metabolism in mice, showed a potential anti-diabetic roles [18]; S-equol showed an anti-breast cancer role via up-regulating miR-10a-5p and inhibiting the PI3K/AKT pathway [22]. This Figure was created in BioRender. (2025) https://BioRender.com/fgldagm (accessed on 25 August 2025).
Nutrients 17 03449 g001
Nutrients 17 03449 g002
Figure 2. The distribution of equol in human foodstuffs.
Figure 2. The distribution of equol in human foodstuffs.
Nutrients 17 03449 g002
Nutrients 17 03449 g003
Figure 3. In vitro production method of Equol. (1) Single-strain. Under anaerobic fermentation conditions at 37 °C, A. equolifaciens subsp. celatus do03 can convert daidzein into equol through dihydrodaidzein (DHD) [33]. Eggerthella sp. YY7918 can synthesize S-equol using daidzein and DHD as substrates under anaerobic conditions [32]. The strain Mt1B8 can convert daidzein and genistein into equol and 5-hydroxy-equol, respectively, through DHD and dihydrogenistein (DHG) under anaerobic conditions [36]. Under anaerobic conditions, Eggerthella sp. DZE can convert daidzein and genistein into (3S)-equol and 5-hydroxy-equol, respectively [37]. Eggerthella sp. Julong732 can convert DHD into S-equol under anaerobic conditions [38]. (2) Co-culture microorganisms. A mixed culture containing four strains (L. mucosae EPI2, E. faecium EPI1, F. magna EPI3, Veillonella sp. EP) can convert daidzein into equol through the DHD pathway. Moreover, the colonic fermentation products of carbohydrates such as hydrogen, butyrate, and propionate can stimulate the production of equol [34]. DHD, dihydrodaidzein; L, Lactobacillus; E, Enterococcus; F, Finegoldia; A, Adlercreutzia.
Figure 3. In vitro production method of Equol. (1) Single-strain. Under anaerobic fermentation conditions at 37 °C, A. equolifaciens subsp. celatus do03 can convert daidzein into equol through dihydrodaidzein (DHD) [33]. Eggerthella sp. YY7918 can synthesize S-equol using daidzein and DHD as substrates under anaerobic conditions [32]. The strain Mt1B8 can convert daidzein and genistein into equol and 5-hydroxy-equol, respectively, through DHD and dihydrogenistein (DHG) under anaerobic conditions [36]. Under anaerobic conditions, Eggerthella sp. DZE can convert daidzein and genistein into (3S)-equol and 5-hydroxy-equol, respectively [37]. Eggerthella sp. Julong732 can convert DHD into S-equol under anaerobic conditions [38]. (2) Co-culture microorganisms. A mixed culture containing four strains (L. mucosae EPI2, E. faecium EPI1, F. magna EPI3, Veillonella sp. EP) can convert daidzein into equol through the DHD pathway. Moreover, the colonic fermentation products of carbohydrates such as hydrogen, butyrate, and propionate can stimulate the production of equol [34]. DHD, dihydrodaidzein; L, Lactobacillus; E, Enterococcus; F, Finegoldia; A, Adlercreutzia.
Nutrients 17 03449 g003
Nutrients 17 03449 g004
Figure 4. The interaction mechanism between microorganisms, gas, and equol. Hydrogen is an important by-product of anaerobic bacterial fermentation and is partially reused by specific intestinal microorganisms. For instance, methanogens can use H2 as an electron donor to reduce CO2, methanol, or acetic acid into methane gas [45,46]; the inhibitory effect of acetic acid on the production of equol may be due to the consumption of hydrogen by bacteria that produce propionic acid or butyric acid. H2 can stimulate equol production by the mixed culture [34]; the count of equol-producing bacteria is negatively correlated with the count of Clostridium coccoides-Eubacterium rectale, and positively correlated with the abundance of sulfate-reducing bacteria [6]; the equol-producing bacterium EPC4 also significantly reduces the generation of methane and hydrogen sulfide in the culture system [44]. This Figure was created in BioRender. (2025) https://BioRender.com/txlg2pd (accessed on 25 August 2025).
Figure 4. The interaction mechanism between microorganisms, gas, and equol. Hydrogen is an important by-product of anaerobic bacterial fermentation and is partially reused by specific intestinal microorganisms. For instance, methanogens can use H2 as an electron donor to reduce CO2, methanol, or acetic acid into methane gas [45,46]; the inhibitory effect of acetic acid on the production of equol may be due to the consumption of hydrogen by bacteria that produce propionic acid or butyric acid. H2 can stimulate equol production by the mixed culture [34]; the count of equol-producing bacteria is negatively correlated with the count of Clostridium coccoides-Eubacterium rectale, and positively correlated with the abundance of sulfate-reducing bacteria [6]; the equol-producing bacterium EPC4 also significantly reduces the generation of methane and hydrogen sulfide in the culture system [44]. This Figure was created in BioRender. (2025) https://BioRender.com/txlg2pd (accessed on 25 August 2025).
Nutrients 17 03449 g004
Nutrients 17 03449 g005
Figure 5. The mechanism of equol synthesis by engineered E. coli. The genes (racemase, tdr, ddr, and dzr) of four enzymes that are involved in the production of equol in A. equolifaciens DSM19450T were synthesized and cloned into a vector (pUC57-Equol) derived from pUC. This vector was introduced into Escherichia coli (E. coli). The recombinant E. coli clone produced equol in a culture medium supplemented with daidzein and dihydrodaidzein [31]. Note: DZNR, Daidzein Reductase; DHDR, Dihydrodaidzein Reductase; THDR, Tetrahydrodaidzein Reductase; DDRC, Dihydrodaidzein Racemase; A, Adlercreutzia; E, Escherichia.
Figure 5. The mechanism of equol synthesis by engineered E. coli. The genes (racemase, tdr, ddr, and dzr) of four enzymes that are involved in the production of equol in A. equolifaciens DSM19450T were synthesized and cloned into a vector (pUC57-Equol) derived from pUC. This vector was introduced into Escherichia coli (E. coli). The recombinant E. coli clone produced equol in a culture medium supplemented with daidzein and dihydrodaidzein [31]. Note: DZNR, Daidzein Reductase; DHDR, Dihydrodaidzein Reductase; THDR, Tetrahydrodaidzein Reductase; DDRC, Dihydrodaidzein Racemase; A, Adlercreutzia; E, Escherichia.
Nutrients 17 03449 g005
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Zhang, T.; Wang, B.; Wang, C.; Bai, J.; Zhou, J.; Chen, J. In Vivo and In Vitro Mechanisms of Equol Synthesis and Key Influencing Factors: A Critical Review. Nutrients 2025, 17, 3449. https://doi.org/10.3390/nu17213449

AMA Style

Zhang T, Wang B, Wang C, Bai J, Zhou J, Chen J. In Vivo and In Vitro Mechanisms of Equol Synthesis and Key Influencing Factors: A Critical Review. Nutrients. 2025; 17(21):3449. https://doi.org/10.3390/nu17213449

Chicago/Turabian Style

Zhang, Tianmeng, Botao Wang, Chen Wang, Junying Bai, Jingwen Zhou, and Jian Chen. 2025. "In Vivo and In Vitro Mechanisms of Equol Synthesis and Key Influencing Factors: A Critical Review" Nutrients 17, no. 21: 3449. https://doi.org/10.3390/nu17213449

APA Style

Zhang, T., Wang, B., Wang, C., Bai, J., Zhou, J., & Chen, J. (2025). In Vivo and In Vitro Mechanisms of Equol Synthesis and Key Influencing Factors: A Critical Review. Nutrients, 17(21), 3449. https://doi.org/10.3390/nu17213449

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop